1. Home
  2. Live Updates
  3. Lara jr

Page 3 - Lara Jr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lara jr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lara Jr Today - Breaking & Trending Today

Investigators Set Sights on Novel Agents Following Negative Studies in Relapsed Small Cell Lung Cancer

New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines. ....

Lara Jr , Larap Jr , Li Zhang , Daniel Morgensztern , European Lung Cancer Congress , Uc Davis School Of Medicine , International Lung Cancer Congress , Davis Comprehensive Cancer Center , Annual International Lung Cancer Congress , Lancet Oncology , Huntington Beach , International Association , Lung Cancer , Lung Cancer Congress , International Lung Cancer Congress ,

Cancer Center, Philippine Oncologists Partner on Latest Treatments

Cancer Center, Philippine Oncologists Partner on Latest Treatments
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Makati City , San Pedro Makati , Kristin Mensonides , Researchmegan Daly , Lara Jr , Primo Lara , Gina Dayton , Pilar Nenucap Almira , Makati Medical Center , Cancer Care Network , Uc Davis Comprehensive Cancer Center , Uc Davis Health Service Lines , Comprehensive Cancer Center , Makati Medical , Multidisciplinary Treatment Approach , Cancer Care , Associate Director , Clinical Researchmegan , Chief Administrative Officer Gina Dayton , Executive Director , Health Service Lines , Regional Affiliates Kristin , Pilar Nenuca ,

Strong Link Between Bone Biomarkers and Prostate Cancer Survival

New study led by UC Davis Comprehensive Cancer Center could improve outcomes for common cancer found in 1 in 8 men. ....

Santa Monica , United States , San Antonio , Northwestern University , Salt Lake City , Catherine Tangen , Jingsong Zhang , Ian Thompson , Neeraj Agarwal , Lara Jr , Erik Gertz , Los Angeles , Edward Mayerson , Michael Leblanc , Mamta Parikh , Maha Hussain , Nicholasj Vogelzang , Amir Goldkorn , Davidi Quinn , Shilpa Gupta , Przemyslaw Twardowski , Las Vegas , Us Department Of Agriculture , Christus Santa Rosa Health System , Cancer Research Network Phase , Human Nutrition Research Center ,

Early-Career Investigators Shine at Cancer Research Mini-Symposium

Early-Career Investigators Shine at Cancer Research Mini-Symposium
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United States , Hanouvi Agbassekou , Soichiro Yamada , Lara Jr , Kirsten Asher , Laura Van Winkle , Fred Meyers , Morgan Domanico , Chenghuiyun Cassie Xu , A Cancer Research Mini , Office Of Education , Mouse Airway Explants , Career Development , Uc Davis Comprehensive Cancer Center , Division Of Hematology Oncology , Uc Davis Health Education Building , Annual Spotlight , Early Career Investigators , Cancer Research Mini Symposium , Health Education , Comprehensive Cancer Center , Paving My Own Path , Dah Som Kim , Comprehensive Cancer Center Director Primo , Asian American , Laura Van ,

UC Davis Health study finds that more bone breakdown predicts shorter lifespan in patients By LILLY ACKERMAN — science@theaggie.org A new study from researchers at the UC Davis Comprehensive Cancer Center has shown that increased bone biomarkers are significantly associated with lowered survival for patients with hormone-sensitive prostate cancer (HSPC). Bone biomarkers are substances that can be seen in urine or blood that indicate the health and activity of bone cells. In the case of prostate cancer, biomarkers can also show signs that the cancer is disrupting bone mass — a common feature of advanced prostate cancer — or that it has spread into a patient's bones. This makes them a promising area of study within prostate cancer treatment research. Dr. Primo "Lucky" Lara Jr., the director of the UC Davis Comprehensive Cancer Center and lead author on the study, said that the prevalence and deadliness of prostate cancer is high compared to other cancer types for males in the United States. "Prostate cancer is the most common cancer diagnosed in men in the United States, accounting for over 288,000 incident cases per year," Lara Jr. said via email. "It is also the second most common cause of cancer death in men, estimated to account for over 34,000 deaths in the U.S. in 2023." Due to the impact that this cancer can have on a patient's bones, biomarkers for bone breakdown have been previously studied for their ability to assess prognosis (a disease's likely progression and outcome), and they have been examined in correlation with responses to therapy. "Bone metastasis is an extremely common event in patients with advanced prostate cancer," Lara Jr. said. "More than 90% of patients with metastatic prostate cancer will have evidence of skeletal involvement." This study focused specifically on biomarkers for bone formation and resorption in advanced or metastatic HSPC patients, looking to see a potential association between disrupted bone turnover and patients' lifespan. The HSPC cancer type refers specifically to patients who have recently been diagnosed with advanced or metastatic prostate cancer but have not yet begun treatment. This is an important classification because further bone imbalances are often caused by the typical treatment for HSPC patients, androgen deprivation therapy (ADT). HSPC survival had not been previously researched for a link with bone biomarkers, unlike castration-resistant prostate cancer (CRPC), for which an association has already been found. CRPC is a form of prostate cancer that continues progressing even after treatment with ADT. The study analyzed results from a phase III clinical trial for ADT. The researchers looked for four different biomarkers in the HSPC patients: two biomarkers for bone loss, and two for bone formation. The researchers found that higher levels of the four circulating bone turnover biomarkers were associated with lowered survival rates in the patients they studied. "Elevated levels of each of the four bone biomarkers [...] showed statistically significant association with worse survival outcomes, independent of traditional clinical risk factors," the study reads. Due to this strong association between a shorter lifespan and high levels of bone biomarkers in HSPC patients, it could be helpful to know the number of biomarkers in patients. Lara Jr. thinks this knowledge might enhance prognosis and counseling during patient visits, as well as offer important value for future trials. If a patient shows more bone biomarker activity, for instance, they can be prioritized so that a trial is completed faster or so they are treated more effectively for their needs. "In the future, clinicians and researchers could use bone biomarkers to guide patient counseling and direct future research efforts," Lara Jr. said. "For example, future early-phase clinical trials can employ this information to identify high-risk groups to screen for new drugs by identifying those with worse prognosis in order to increase the pace of the trial and complete study accrual sooner." Written by: Lilly Ackerman — science@theaggie.org

UC Davis Health study finds that more bone breakdown predicts shorter lifespan in patients   By LILLY ACKERMAN science@theaggie.org    A new ....

United States , Lara Jr , Uc Davis Health , Uc Davis Comprehensive Cancer Center , Comprehensive Cancer Center ,